Basis for antibody- and hormone-mediated activation of TSHR in Graves’ disease

Jia Duan, Peiyu Xu, Xiaodong Luan, Yujie Ji, Qingning Yuan, Xinheng He, Ye Jin, Xi Cheng, Hualiang Jiang, Yuanqiang Zhang, Yi Jiang, H. Eric XubioRxiv 2022 · DOI

TL;DR

This paper presents the cryo-EM structures of the TSH receptor (TSHR) bound to its natural ligand (TSH), an activating autoantibody (M22), and an inhibitory antibody (K1-70). These structures reveal a conserved "push and pull" mechanism for activating glycoprotein hormone receptors and provide a molecular basis for Graves' disease, a condition caused by autoantibodies targeting TSHR.

What Problem Does This Paper Address?

Graves' disease is an autoimmune disorder affecting millions worldwide, characterized by the overproduction of thyroid hormones. This overproduction is driven by autoantibodies that mistakenly activate the TSH receptor (TSHR), mimicking the action of the natural hormone TSH. While the clinical consequences are well-known, the precise molecular mechanisms by which TSH and these autoantibodies activate TSHR, and how inhibitory antibodies block this activation, have remained largely unknown. Understanding these mechanisms is crucial for developing targeted therapies.

Methods

The researchers employed cryo-electron microscopy (cryo-EM) to determine high-resolution structures of TSHR in complex with various ligands:

  • TSH-TSHR-Gs complex: This structure reveals how the natural hormone TSH activates the receptor and couples to the intracellular Gs protein.
  • M22_ScFv-TSHR-Gs complex: This structure shows how an activating autoantibody (M22) from Graves' disease patients binds and activates TSHR.
  • K1-70-TSHR complex: This structure illustrates how an inhibitory autoantibody (K1-70) from hypothyroidism patients blocks TSHR activation.

They also performed functional assays, such as cAMP response assays, to correlate structural findings with biological activity. Site-directed mutagenesis was used to probe the roles of specific residues in ligand binding and receptor activation.

Datasets

The study utilized purified protein complexes for cryo-EM imaging. The datasets generated were the cryo-EM density maps and atomic coordinates of the determined structures. These have been deposited in public databases (EMDB and PDB) for broader scientific access. No new benchmarks were introduced; rather, existing structures of related receptors (LHCGR, FSHR) were used for comparative analysis.

Key Insights and Ideas

  • Universal "Push and Pull" Mechanism: The structures reveal that both TSH and the activating autoantibody M22 activate TSHR by "pushing" the extracellular domain (ECD) into an upright conformation. This push is complemented by a "pull" mechanism involving interactions with the hinge region of the receptor. This conserved mechanism appears to be shared across glycoprotein hormone receptors.
  • Cholesterol's Role in Localization: A surprising finding was the presence of over 15 cholesterol molecules surrounding the TSHR transmembrane domain. This suggests that TSHR is preferentially localized in cholesterol-rich lipid rafts, which are known to be important signaling platforms.
  • Distinct Antibody Mechanisms: The activating antibody M22 and the inhibitory antibody K1-70 employ different strategies. M22 appears to destabilize the inactive TSHR conformation and stabilize the active one, while K1-70 binds to a region that overlaps with TSH binding, effectively blocking hormone interaction.
  • Structural Basis for Selectivity: The comparison of TSHR with the related LHCGR reveals subtle differences in the binding pocket that explain the selectivity of small molecule agonists like ML-109 for TSHR.

Key Results

  • High-Resolution Structures: The study determined cryo-EM structures of TSHR complexes at resolutions ranging from 2.39 Å to 5.46 Å, providing detailed atomic insights.
  • TSH Activation: TSH binding induces a ~38° rotation of the TSHR ECD to an active, upright conformation.
  • M22 Activation: The activating antibody M22 also induces an upright conformation, similar to TSH, and exhibits comparable potency in activating TSHR.
  • K1-70 Inhibition: The inhibitory antibody K1-70 binds to the TSHR ECD and blocks TSH binding, preventing receptor activation.
  • Mutational Analysis: Mutations in the hinge region (D386G, Y385G, Y387G) significantly reduced TSH activation potency, supporting the "pull" mechanism. Mutations in TM6 were linked to constitutive activation, highlighting the importance of this transmembrane helix in receptor dynamics.

Limitations and Future Work

  • Inactive TSHR Structure: While an inactive TSHR structure was obtained in complex with the inhibitory antibody K1-70, obtaining a truly apo-inactive TSHR structure proved challenging.
  • Dynamic Nature: The presented structures represent snapshots; further studies could explore the dynamic transitions of TSHR activation.
  • Therapeutic Implications: The authors suggest that these structural insights provide a foundation for developing novel therapeutics targeting TSHR for Graves' disease and hypothyroidism, potentially through small molecule modulators or antibody-based therapies. Future work could focus on designing more specific and potent agonists or antagonists based on these structural findings.

Summary updated

Abstract

Thyroid stimulating hormone (TSH), through activation of its G protein-coupled receptor TSHR, controls the synthesis of thyroid hormone (TH), an essential metabolic hormone. Aberrant signaling of TSHR by autoantibodies causes Graves’ disease and hypothyroidism that affect millions of patients worldwide. Here we report the active structures of TSHR with TSH and an activating autoantibody M22, both bound to an allosteric agonist ML-109, as well as an inactive TSHR structure with inhibitory antibody K1-70. Both TSH and M22 push the extracellular domain (ECD) of TSHR into the upright active conformation. In contrast, K1-70 blocks TSH binding and is incapable of pushing the ECD to the upright conformation. Comparisons of the active and inactive structures of TSHR with those of the luteinizing hormone–choriogonadotropin receptor (LHCGR) reveal a universal activation mechanism of glycoprotein hormone receptors, in which a conserved 10-residue fragment (P10) from the hinge C-terminal loop mediated interactions from the receptor ECD to its transmembrane domain. One surprisingly feature is that there are over 15 cholesterols surrounding TSHR, supporting its preferential location in lipid rafts. These structures also highlight a common mechanism for TSH and autoantibody M22 to activate TSHR, thus providing the molecular basis for Graves’ disease.
BibTeX
@misc{duan2022basis,
  author = {Jia Duan and Peiyu Xu and Xiaodong Luan and Yujie Ji and Qingning Yuan and Xinheng He and Ye Jin and Xi Cheng and Hualiang Jiang and Yuanqiang Zhang and Yi Jiang and H. Eric Xu},
  title = {{Basis for antibody- and hormone-mediated activation of TSHR in Graves’ disease}},
  year = {2022},
  doi = {10.1101/2022.06.13.496020},
  howpublished = {bioRxiv},
}
Figure